How I Treat: Transplantation for primary immune regulatory diseases and inflammatory disorders.

Authors

Joseph Hai Oved

Published in

Journal of human immunity. Volume 2. Issue 6. Nov 02, 2026. Epub Oct 05, 2026.

Abstract

Primary immune regulatory disorders (PIRDs), autoinflammatory, and hyperinflammatory syndromes can be life-threatening and/or significantly impact quality of life. Targeted immune modulation may control symptoms for some, but allogeneic hematopoietic stem cell transplantation (alloHCT) remains the only cure for many patients. Despite advances in alloHCT, outcomes for this population continue to need optimization. Focus areas include referral timing, patient selection, multidisciplinary evaluation, targeted pretransplant immune suppression (PTIS), graft selection, model- and exposure-based conditioning, and post-alloHCT management. Here, we describe our preferred alloHCT approach for this patient population. This includes early alloHCT referral, continued evaluation to identify an appropriate alloHCT window, 6-12 wk of targeted PTIS for inflamed patients, a myeloablative model-based reduced-toxicity conditioning regimen, a strong index of suspicion for posttransplant immune dysregulation, and multidisciplinary long-term follow-up. Emphasis is placed on the need for predictive biomarkers to guide clinical decision-making, objective measurements of long-term response/disease resolution, and prospective multicenter trials. By refining our approaches, curative outcomes will continue to improve.

PMID:
42831798
Bibliographic data and abstract were imported from PubMed on 05 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.